IDEAYA Biosciences (IDYA)
34.71
-1.41 (3.90%)
Upcoming Events
Latest Headlines
IDEAYA's IDE849 shows early survival data in relapsed lung cancer
October 23, 2026 6:00 AM - StreetInsider
IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroend
October 23, 2026 6:00 AM - PR NewsWire
IDEAYA shares uveal melanoma trial data from three studies at ESMO
October 19, 2026 6:02 AM - StreetInsider
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Jou
October 19, 2026 6:00 AM - PR NewsWire
Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens - Ph2 OptiMUM-01 Results Coming Up
October 19, 2026 4:22 AM - StreetInsider
William Blair Starts Ideaya Biosciences (IDYA) at Outperform
October 16, 2026 2:53 AM - StreetInsider
Stifel Starts Ideaya Biosciences (IDYA) at Buy
October 13, 2026 4:07 PM - StreetInsider
Form 4 IDEAYA Biosciences, Inc. For: Oct 06 Filed by: Hata Yujiro S
October 8, 2026 7:04 PM - SEC Filing
Form 144 IDEAYA Biosciences, Inc. Filed by: Hata Yujiro S
October 6, 2026 4:13 PM - SEC Filing
Ideaya Biosciences (IDYA) Reiterated at Overweight by Cantor Fitzgerald
October 6, 2026 7:40 AM - StreetInsider
Ideaya Biosciences promotes chief scientific officer to president of R&D
September 28, 2026 6:00 AM - StreetInsider
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
September 28, 2026 6:00 AM - PR NewsWire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 25, 2026 11:32 AM - PR NewsWire
Ideaya Biosciences (IDYA) Reiterated at Overweight by Cantor Fitzgerald
September 22, 2026 8:03 AM - StreetInsider
Ideaya Biosciences (IDYA) PT Raised to $57 at Guggenheim
September 9, 2026 7:12 AM - StreetInsider
Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens on IDE849 Advances
September 1, 2026 4:23 AM - StreetInsider
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 28, 2026 6:00 AM - PR NewsWire
IDEAYA and Genentech to test drug combo in pancreatic cancer
August 19, 2026 6:01 AM - StreetInsider
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
August 19, 2026 6:00 AM - PR NewsWire
Form SCHEDULE 13G IDEAYA Biosciences, Inc. Filed by: BAKER BROS. ADVISORS LP
August 14, 2026 4:03 PM - SEC Filing
Form 10-Q IDEAYA Biosciences, Inc. For: Jun 30
August 4, 2026 4:07 PM - SEC Filing
IDEAYA Biosciences (IDYA) Misses Q2 EPS by 16c
August 4, 2026 6:19 AM - StreetInsider
Form 8-K IDEAYA Biosciences, Inc. For: Aug 04
August 4, 2026 6:05 AM - SEC Filing
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
August 4, 2026 6:00 AM - PR NewsWire
Form SCHEDULE 13G IDEAYA Biosciences, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
July 31, 2026 10:18 AM - SEC Filing
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 31, 2026 6:00 AM - PR NewsWire
IDEAYA Biosciences starts Phase 1/2 expansion for IDE892 in cancer
July 27, 2026 6:00 AM - StreetInsider
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancer
July 27, 2026 6:00 AM - PR NewsWire
Full Article List
